Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth,...

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Vascular endothelial growth factor (VEGF) drives tumor growth by promoting new blood vessel formation (angiogenesis).
• Elevated VEGF expression is common in solid tumors, supporting their neovascularization and progression.

Purpose of the Study:

• To investigate the potential of soluble FLT-1 (sFLT-1) gene therapy to inhibit tumor growth by targeting VEGF-dependent angiogenesis.
• To evaluate the efficacy of sFLT-1 in reducing tumor implantation, growth, and improving survival in preclinical models.

Main Methods:

• HT-1080 fibrosarcoma and human glioblastoma cells were transfected with cDNA encoding sFLT-1.
• Tumor cell implantation and growth were assessed in nude mice following intravenous and subcutaneous injections.
• Survival rates were analyzed in mice with intracranial glioblastoma xenografts.

Main Results:

• Transient and stable transfection with sFLT-1 significantly inhibited tumor cell implantation and growth in vivo.
• sFLT-1 expression led to slower tumor growth in subcutaneous models.
• Survival was significantly prolonged in mice bearing intracranial glioblastoma tumors treated with sFLT-1 gene therapy.

Conclusions:

• Soluble FLT-1 acts as an anti-angiogenic agent by sequestering VEGF and interfering with VEGF receptor function.
• sFLT-1 gene therapy demonstrates feasibility for inhibiting tumor angiogenesis and growth, supporting VEGF receptors as viable anti-cancer targets.